Bristol-Myers Squibb (BMY) won the dismissal of a proposed class-action lawsuit in a federal court accusing it of using anticompetitive tactics to maintain monopoly on its blood cancer drug Pomalyst, multiple media outlets reported Wednesday.
US District Judge Edgardo Ramos in New York City said in a 70-page decision that Blue Cross Blue Shield of Louisiana and other Pomalyst purchasers failed to show that the company violated the federal Sherman act, Reuters reported.
Filed in September 2023, the suit claimed the drug to have been subject to generic competition by October 2020 and Bristol-Myers' tactics caused these companies to overpay by hundreds of millions, Fierce Pharma reported.
The lawsuit accused Bristol-Myers of obtaining illegal patents to the drug and then in order to maintain a monopoly filing sham lawsuits against generic drugmakers.
Price: 53.12, Change: +0.05, Percent Change: +0.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。